A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
This open-label, multi-center, three-period, one-sequence study will investigate the effect
of rifampin on the PK of vemurafenib in participants with unresectable BRAFV600-mutation
positive metastatic melanoma or other malignant tumor type that harbors a V600-activating
mutation of BRAF without acceptable standard treatment options. Eligible participants will
have the option to continue treatment with vemurafenib as part of an extension study GO28399
(NCT01739764).